Commentary: FDA should allow more off-label use of cancer drugs

FDA leaders Drs. Margaret Hamburg and Joshua Sharfstein should consider allowing patients access to cancer drugs that have proven effective in certain indications even if such uses have not been approved by the agency, writes Richard Epstein, a law professor at the University of Chicago and a senior fellow at Stanford University's Hoover Institution. The FDA can collaborate with the National Comprehensive Cancer Network, a group of 21 cancer centers, to offer cancer drugs that have gone through Phase I clinical trials so more patients can benefit from the treatments, Epstein writes.

View Full Article in:

Wall Street Journal (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
ISHN - Chief Compliance Officer
Mountain States Health Alliance
Johnson City, TN
Meridian Health Plan
Detroit, MI
President/Chief Executive Officer
Winston-Salem, NC
Director, Payer Marketing
Avalere Health
Washington, DC